Skip to main content

Advertisement

Table 1 Comparison of clinical features between MDS patients with and without DNMT3A mutation

From: Dynamics of DNMT3A mutation and prognostic relevance in patients with primary myelodysplastic syndrome

Variables Total DNMT3A mutated DNMT3A wild P value
(n = 469) (n = 37, 7.9%) (n = 432, 92.1%)
Gender     0.201
 Male 315 (67.2) 21 (6.7) 294 (93.3)  
 Female 154 (32.8) 16 (10.4) 138 (89.6)  
Age (year)# 65.5 (16~98) 69.6 (35~89) 65.5 (16~98) 0.151
Lab data#
 WBC (× 109/L) 3.84 (0.44~355.3) 5.02 (0.49~59.83) 3.73 (0.44~355.3) 0.942
 Hb (g/dL) 8.3 (3~15) 8.1 (5~11) 8.3 (3~15) 0.555
 Platelet (× 109/L) 74 (2~931) 162 (14~460) 74 (2~931) 0.045
 LDH (mckat/L) 8.133 (2.422~113.677) 8.208 (3.507~24.733) 8.133 (2.422~113.677) 0.739
FAB subtype††     0.002
 RA 171 (36.5) 4 (2.3) 167 (97.7) 0.001
 RARS 32 (6.8) 6 (18.8) 26 (81.2) 0.031
 RAEB 159 (33.9) 18 (11.3) 141 (88.7) 0.069
 RAEB-T 53 (11.3) 5 (9.4) 48 (90.6) 0.593
 CMML 54 (11.5) 4 (7.4) 50 (92.6) > 0.999
2016 WHO classification †† (n = 362) (n = 28, 7.7%) (n = 334, 92.3%) 0.011
 MDS-SLD 60 (16.6) 1 (1.7) 59 (98.3) 0.062
 MDS-MLD 106 (29.3) 3 (2.8) 103 (97.2) 0.029
 MDS-RS-SLD 18 (5.0) 3 (16.7) 15 (83.3) 0.154
 MDS-RS-MLD 13 (3.6) 3 (23.1) 10 (76.9) 0.070
 MDS with isolated del(5q) 2 (0.6) 0 (0.0) 2 (100.0) > 0.999
 MDS-EB-1 78 (21.5) 8 (10.3) 70 (89.7) 0.343
 MDS-EB-2 81 (22.4) 10 (12.3) 71 (87.7) 0.097
 MDS-U 4 (1.1) 0 (0.0) 4 (100.0) > 0.999
Karyotype risk†† Φ (n = 437) (n = 35) (n = 402) 0.883
 Good 263 (60.2) 20 (7.6) 243 (92.4) 0.721
 Intermediate 88 (20.1) 7 (8.0) 81 (92.0) > 0.999
 Poor 86 (19.7) 8 (9.3) 78 (90.7) 0.658
IPSS†† § (n = 437) (n = 35) (n = 402) 0.372
 Low 68 (15.6) 4 (5.9) 64 (94.1) 0.630
 INT-1 181 (41.4) 11 (6.0) 170 (94.0) 0.283
 INT-2 107 (24.5) 11 (10.3) 96 (89.7) 0.412
 High 81 (18.5) 9 (11.1) 72 (88.9) 0.259
IPSS-R††ζ (n = 437) (n = 35) (n = 402) 0.692
 Very low 13 (3.0) 1 (7.7) 12 (99.3) > 0.999
 Low 104 (23.8) 7 (6.7) 97 (93.3) 0.682
 Intermediate 106 (24.2) 6 (5.7) 100 (94.3) 0.411
 High 113 (25.9) 10 (8.8) 103 (91.2) 0.841
 Very high 101 (23.1) 11 (10.9) 90 (89.1) 0.294
  1. Abbreviations: FAB, French-American-British classification; RA, refractory anemia; RARS, refractory anemia with ring sideroblasts; RAEB, refractory anemia with excess blasts; RAEB-T, refractory anemia with excess blasts in transformation; CMML, chronic myelomonocytic leukemia; MDS-SLD, MDS with single lineage dysplasia; MDS-MLD, MDS with multilineage dysplasia; MDS-RS-SLD, MDS with ring sideroblasts with single lineage dysplasia; MDS-RS-MLD, MDS with ring sideroblasts with multilineage dysplasia; MDS-EB1 , MDS with excess blasts-1; MDS-EB2, MDS with excess blasts-2; MDS-U, MDS, unclassified
  2. Number of patients (% among the males or females)
  3. #Median (range)
  4. ††Number of patients (% among patients of each subgroup)
  5. ΦGood: normal karyotype, isolated -Y, del(5q), or del(20q); Poor: complex ( 3 abnormalities) or chromosome 7 anomalies; Intermediate, other abnormalities
  6. § IPSS (international prognosis scoring system): low, 0; intermediate (INT)-1, 0.5–1; INT-2, 1.5–2; and high, ≥ 2.5
  7. ζ IPSS-R (revised international prognostic scoring system): very low, 1.5; low, > 1.5–3; intermediate, > 3–4.5; high, > 4.5–6; and very high, > 6